中国实用外科杂志

中国实用外科杂志 ›› 2021, Vol. 41 ›› Issue (09): 1056-1061.DOI: 10.19538/j.cjps.issn1005-2208.2021.09.13

• 文献综述 • 上一篇    下一篇

胆道恶性肿瘤免疫治疗进展

谢智华，程庆保，姜小清   

  1. 海军军医大学第三附属医院 东方肝胆外科医院胆道一科，上海200438
  • 出版日期:2021-09-01 发布日期:2021-10-19

  • Online:2021-09-01 Published:2021-10-19

摘要： 胆道恶性肿瘤发病率逐年升高，其异质性高，早期诊断困难，一经确诊多为晚期。晚期胆道肿瘤病人临床治疗手段有限，预后差。以吉西他滨或氟脲类为基础的药物化疗是该类病人的基础化疗方案，国内外尚无针对胆道肿瘤标准的一、二线治疗方案的结论。近年来精准治疗和免疫治疗在多种恶性实体肿瘤中取得了很大的突破，在晚期胆道肿瘤中也显示了初步的疗效及较好的安全性，为晚期胆道肿瘤的治疗带来了新的希望。

关键词: 胆管癌, 胆道肿瘤, 免疫治疗, 免疫检查点抑制剂

Abstract: Immunotherapy of biliary tract cancer: perspectives and issues        XIE Zhi-hua，CHENG Qing-bao，JIANG Xiao-qing.   Department of Biliary Tract Surgery I, Eastern Hepatobiliary Surgery Hospital, the Second Military Medical University, Shanghai 200438, China
Corresponding author：JIANG Xiao-qing，E-mail:jxq1225@
sina.com
Abstract    The incidence of biliary malignant tumors is increasing year by year，and the heterogeneity is high,  early diagnosis is difficult and usually diagnosed at an advanced stage. Patients with advanced biliary tract cancers have limited clinical treatment options and poor prognosis. Drug chemotherapy based on gemcitabine or fluorourea is the basic chemotherapy regimen for this type of patients. There is still no standard first-line and second-line treatment for biliary tract tumors at home and abroad. In recent years，precision therapy and immunotherapy have made great breakthroughs in a variety of malignant solid tumors. It has also shown preliminary efficacy and better safety in advanced biliary tract cancers，which brings new sight for the treatment of advanced biliary tract cancers.

Key words: cholangiocarcinoma, biliary tract tumors, immunity therapy, immune checkpoint inhibitor ,